India, May 1 -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company, Thursday reported first-quarter net loss of $29.8 million or $0.20 per share, compared to $47.5 million or $0.33 per share for the same period in 2024.
Revenue was $52.4 million for the quarter, representing a 25% increase from $41.9 million in the first quarter in the prior year.
MRD revenue was $43.7 million for the quarter, representing a 34% increase from the first quarter in the prior year. Immune Medicine revenue was $8.7 million for the quarter, representing a 6% decrease from the first quarter in the prior year.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Adaptive Biotechnologies expects...